(BOSTON) – CARB-X is awarding Novel Microdevices, Inc. of Baltimore, Maryland, USA, up to $3.6 million in non-dilutive funding, and, subject to available funding, up to an additional $10.2 million if certain project milestones are met, to develop a new rapid molecular test to diagnose sexually-transmitted bacterial infections, including Chlamydia trachomatis and Neisseria gonorrhoeae. Novel’s new device would diagnose infections in about 25 minutes from a vaginal swab or urine sample, and detect antibiotic-resistant bacteria, including those resistant to ciprofloxacin and 3rd generation cephalosporins, the only antibiotics that are still effective as treatments for most strains of the gonorrhoeae bacteria.
Image: https://carb-x.org
{iframe}https://carb-x.org/carb-x-news/carb-x-is-funding-novel-microdevices-to-develop-a-rapid-and-portable-diagnostic-for-sexually-transmitted-diseases-including-antibiotic-resistant-infections/{/iframe}